IPOs: China Biotechs Abandon New York for Hong Kong
Bottom line: Two biotech firms' abandonment of New York IPOs for Hong Kong is part of a broader trend to make Hong Kong and China more competitive for high-growth startups, and could ultimately boost valuations in all three markets.
We'll take a break from all the trade war talk as we close out the week and instead turn to another major development taking place in Hong Kong, where the local sto...